학술논문
Gene expression profiling predicts relapse‐free and overall survival in newly diagnosed myeloma patients treated with novel therapies.
Document Type
Article
Author
Manasanch, Elisabet E.; Berrios, David; Fountain, Eric; Claussen, Catherine M.; Chuang, Tammy; Kaufman, Gregory; Amini, Behrang; Bashir, Qaiser; Nieto, Yago; Qazilbash, Muzaffar; Patel, Krina; Thomas, Sheeba K.; Weber, Donna M.; Berkova, Zuzana; Toruner, Gokce; Lin, Pei; Feng, Lei; Lee, Hans C.; Orlowski, Robert Z.; Kunacheewa, Chutima
Source
Subject
*GENE expression profiling
*FLUORESCENCE in situ hybridization
*
Language
ISSN
0007-1048
Abstract
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies In addition, the LR FISH/HR GEP had a relapse rate at 12 months of 30% (3/12 patients) I versus i 0% in patients with LR GEP/HR FISH (0/8 patients; B Table b IA B ) b . Patients with HR GEP/HR FISH demonstrated reduced RFS and OS when compared to LR GEP/FISH with HR GEP being the best predictor of early RFS. For example, patients with HR GEP had a death rate due to multiple myeloma (MM) of 21% (HR GEP/HR FISH), 25% (HR GEP/LR FISH), 0% (LR GEP/HR FISH) and 6% (LR GEP/LR FISH) ( I P i = 0-03; B Table b IB B ) b . [Extracted from the article]